Ontuxizumab[1] is a humanized rabbit monoclonal antibody[2] designed for the treatment of cancer.
[3] Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma.
It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.
[4] This drug was developed by Morphotek and Ludwig Institute for Cancer Research.
[4] This monoclonal antibody–related article is a stub.